Atkinson's principles of clinical pharmacology / (Record no. 9445)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 10546nam a22003375i 4500 |
| 001 - CONTROL NUMBER | |
| control field | 22162510 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | ZET-ke |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250127144257.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 210803s2021 mau 000 0 eng |
| 010 ## - LIBRARY OF CONGRESS CONTROL NUMBER | |
| LC control number | 2021944333 |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 9780128198698 |
| Qualifying information | (hardback) |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| Cancelled/invalid ISBN | 9780128198841 |
| Qualifying information | (epub) |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | DLC |
| Language of cataloging | eng |
| Description conventions | rda |
| Transcribing agency | DLC |
| Modifying agency | ZET-ke |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | pcc |
| 050 ## - LIBRARY OF CONGRESS CALL NUMBER | |
| Classification number | RM 105 |
| Item number | .A85 2022 |
| 245 00 - TITLE STATEMENT | |
| Title | Atkinson's principles of clinical pharmacology / |
| Statement of responsibility, etc | Shiew Mei Huang, Juan J.L Lertora, Paolo Vicini, Arthur J Atkinson, Jr. |
| 250 ## - EDITION STATEMENT | |
| Edition statement | 4. |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. (IMPRINT) | |
| Place of publication, distribution, etc | London, United Kingdom: |
| Name of publisher, distributor, etc | Academic Press, |
| Date of publication, distribution, etc | 2022. |
| 263 ## - PROJECTED PUBLICATION DATE | |
| Projected publication date | 2109 |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | xxi, 738p. |
| Other physical details | ill. |
| Dimensions | 29cm. |
| 504 ## - BIBLIOGRAPHY, ETC. NOTE | |
| Bibliography, etc | Includes bibliographical references and indexes. |
| 505 ## - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Intro<br/>Atkinson's Principles of Clinical Pharmacology<br/>Copyright<br/>Contents<br/>Contributors<br/>Preface to the first edition<br/>Preface to the fourth edition<br/>Chapter 1: Introduction to clinical pharmacology<br/>Background<br/>Optimizing use of existing medicines<br/>Evaluation and development of medicines<br/>Pharmacokinetics<br/>The concept of clearance<br/>Clinical estimation of renal function<br/>Dose-related toxicity often occurs when impaired renal function is unrecognized<br/>References<br/>Additional sources of information<br/>Chapter 2: Clinical pharmacokinetics<br/>The target concentration strategy<br/>Monitoring serum concentrations of digoxin as an example<br/>General indications for drug concentration monitoring<br/>Concepts underlying clinical pharmacokinetics<br/>Initiation of drug therapy (concept of apparent distribution volume)<br/>Continuation of drug therapy (concepts of elimination half-life and clearance)<br/>Elimination half-life<br/>Elimination clearance<br/>Drugs not eliminated by first-order kinetics<br/>Mathematical basis of clinical pharmacokinetics<br/>First-order elimination kinetics<br/>Concept of elimination half-life<br/>Relationship of k to elimination clearance<br/>Cumulation factor<br/>The plateau principle<br/>Application of Laplace transforms to pharmacokinetics<br/>References<br/>Study problems<br/>Chapter 3: Compartmental analysis of drug distribution<br/>Fit-for-purpose modeling of drug distribution<br/>Physiological significance of drug distribution volumes<br/>Physiological basis of multicompartmental models of drug distribution<br/>Formulation of multicompartmental models<br/>Basis of multicompartmental structure<br/>Mechanisms of transcapillary exchange<br/>Clinical consequences of different drug distribution patterns<br/>Drugs with faster elimination than distribution<br/>Estimating model parameters from experimental data. Derivation of equations for a two-compartment model<br/>Calculation of rate constants and compartment volumes from data<br/>Different estimates of apparent volume of distribution<br/>References<br/>Study problems<br/>Chapter 4: Drug absorption and bioavailability<br/>Drug absorption<br/>Metabolism by intestinal bacteria<br/>Presystemic elimination<br/>Drug-drug and food-drug interactions<br/>Bioavailability<br/>Absolute bioavailability<br/>Relative bioavailability<br/>In vitro prediction of bioavailability<br/>Kinetics of drug absorption after oral administration<br/>Time to peak level<br/>Value of peak level<br/>Use of convolution/deconvolution to assess in vitro-in vivo correlations<br/>References<br/>Study problems<br/>Chapter 5: Effect of kidney disease on pharmacokinetics<br/>Drug dosing in patients with impaired kidney function<br/>Effects of kidney disease on renal drug elimination mechanisms<br/>Excretion mechanisms: Filtration and secretion<br/>Reabsorption mechanisms<br/>Renal metabolism<br/>Analysis and interpretation of renal excretion data<br/>Effects of impaired kidney function on nonrenal clearance pathways<br/>Nonrenal metabolism<br/>Nonrenal transport<br/>Potential mechanisms of altered nonrenal clearance<br/>Effects of kidney disease on drug distribution<br/>Plasma protein binding of acidic drugs<br/>Plasma protein binding of basic and neutral drugs<br/>Tissue binding of drugs<br/>Effects of kidney disease on drug absorption<br/>Study problem<br/>References<br/>Chapter 6: Pharmacokinetics in patients requiring renal replacement therapy<br/>Kinetics of intermittent hemodialysis<br/>Solute transfer across dialyzing membranes<br/>Calculation of dialysis clearance<br/>Patient factors affecting hemodialysis of drugs<br/>Hemodynamic changes during Dialysis<br/>Kinetics of CRRT and sustained renal replacement therapy<br/>Clearance by continuous hemofiltration. Clearance by continuous hemodialysis and SLED<br/>Extracorporeal clearance during continuous renal replacement therapy<br/>Clinical considerations<br/>Drug dosing guidelines for patients requiring renal replacement therapy<br/>Extracorporeal therapy of patients with drug toxicity<br/>References<br/>Chapter 7: Effect of liver disease on pharmacokinetics<br/>Physiologic determinants of hepatic drug clearance<br/>Hepatic elimination of drugs<br/>Restrictively metabolized drugs (ER0.3)<br/>Effect of changes in protein binding on hepatic clearance<br/>Effect of changes in intrinsic clearance on hepatic drug clearance<br/>Drugs with an intermediate extraction ratio (0.3ER0.7)<br/>Nonrestrictively metabolized drugs (ER0.70)<br/>Biliary excretion of drugs<br/>Enterohepatic circulation<br/>Effects of liver disease on pharmacokinetics<br/>Acute hepatitis<br/>Chronic liver disease and cirrhosis<br/>Pharmacokinetic consequences of liver cirrhosis<br/>Influence of portosystemic shunting on nonrestrictively metabolized drugs<br/>Consequences of decreased protein binding<br/>Consequences of hepatocellular changes<br/>Use of therapeutic drugs in patients with liver disease<br/>Classification schemes for liver function<br/>FDA guidance for industry on pharmacokinetic studies in patients with impaired hepatic function<br/>Other tools for the assessment of liver function<br/>Effects of liver disease on the hepatic elimination of drugs<br/>Correlation of laboratory tests with drug metabolic clearance<br/>Use of probe drugs to characterize hepatic drug clearance<br/>Effects of liver disease on the renal elimination of drugs<br/>Effects of liver disease on patient response<br/>Modification of drug therapy in patients with liver disease<br/>References<br/>Chapter 8: Noncompartmental and compartmental approaches to pharmacokinetic data analysis<br/>Introduction. Kinetics, pharmacokinetics, and pharmacokinetic parameters<br/>Kinetics and the link to mathematics<br/>The pharmacokinetic parameters<br/>Accessible pool parameters<br/>System parameters<br/>Moments<br/>Noncompartmental analysis<br/>Noncompartmental model<br/>Kinetic parameters of the noncompartmental model<br/>The single accessible pool model<br/>The two accessible pool model<br/>Estimating the kinetic parameters of the noncompartmental model<br/>Estimating AUC and AUMC using sums of exponentials<br/>Estimating AUC and AUMC using other functions<br/>Estimating t1tnC(t)dt and t1tntC(t)dt<br/>Extrapolating from tn to infinity<br/>Estimating AUC and AUMC from 0 to infinity<br/>Compartmental analysis<br/>Definitions and assumptions<br/>Linear, constant coefficient compartmental models<br/>Parameters estimated from compartmental models<br/>Experimenting on compartmental models: Input and measurements<br/>Nonlinearities in compartmental models<br/>Calculating pharmacokinetic parameters from a compartmental model<br/>Model parameters<br/>Residence time calculations<br/>Noncompartmental versus compartmental models<br/>Models of data vs. models of system<br/>The equivalent sink and source constraints<br/>Linearity and time invariance<br/>Recovering pharmacokinetic parameters from compartmental models<br/>Conclusion<br/>References<br/>Chapter 9: Population pharmacokinetics<br/>Introduction<br/>Analysis of pharmacokinetic data<br/>Structure of pharmacokinetic models<br/>Fitting individual data<br/>Population pharmacokinetics<br/>Population analysis methods<br/>The naïve pooled data method<br/>The two-stage method<br/>Nonlinear mixed effects modeling method<br/>Model comparison<br/>Model evaluation<br/>Model applications<br/>Mirogabalin case study<br/>Milademetan case study<br/>Conclusions<br/>References<br/>Chapter 10: Pathways of drug metabolism<br/>Introduction. The chemistry and enzymology of drug metabolism<br/>Oxidations and nonconjugation reactions<br/>Cytochrome P450 monooxygenases<br/>Cytochrome P450 families<br/>The CYP3A family<br/>The CYP2C family<br/>The CYP2D6 family<br/>The CYP 1A family<br/>Non-CYP oxidations<br/>Flavin-containing monooxygenases<br/>Monoamine oxidases<br/>Molybdenum-containing oxidases<br/>Esterases<br/>Epoxide hydrolases<br/>Conjugation reactions<br/>Glucuronosyl transferases<br/>Sulfotransferases<br/>Acetyl transferases<br/>Methyltransferases<br/>Glutathione transferases<br/>References<br/>Chapter 11: Bioanalytical methods: Technological platforms and method validation<br/>Technological platforms of bioassays<br/>High performance/pressure liquid chromatography<br/>Chromatographic column<br/>Mobile phase<br/>Detectors<br/>Alternative chromatographic approaches<br/>Gas chromatography<br/>LC-MS/MS and high resolution mass spectrometry (HRMS)<br/>Internal standards<br/>Accelerator mass spectrometry<br/>Immunoassays<br/>Polymerase chain reaction assays<br/>Method validation<br/>Sample analysis<br/>Cross-validation<br/>Case examples<br/>Interference<br/>Establishing assay range<br/>Impact of sample handling or instability<br/>Assessing results from two assays: Cross-validation<br/>Conclusion<br/>References<br/>Chapter 12: Clinical pharmacogenetics<br/>Introduction<br/>General principles<br/>Pharmacogenetics and pharmacogenomics<br/>Human genetics<br/>Indications for performing pharmacogenetic studies<br/>Genetic analysis techniques and informatics<br/>Examples of clinically relevant genetic polymorphisms<br/>Genetic variation in Phase I metabolic pharmacogenes<br/>CYP2B6<br/>CYP2C9<br/>CYP2C19<br/>CYP2D6<br/>CYP3A4 and CYP3A5<br/>Genetic variation in Phase II metabolic pharmacogenes<br/>Thiopurine S-methyltransferase (TPMT)<br/>N-Acetyltransferase 2 (NAT2)<br/>Target/efficacy pharmacogenetics |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc | "Atkinson's Principles of Clinical Pharmacology, Fourth Edition is the essential reference on the pharmacologic principles underlying the individualization of patient therapy and contemporary drug development. This well-regarded survey continues to focus on the basics of clinical pharmacology for the development, evaluation and clinical use of pharmaceutical products while also addressing the most recent advances in the field. Written by leading experts in academia, industry, clinical and regulatory settings, the fourth edition has been thoroughly updated to provide readers with an ideal reference on the wide range of important topics impacting clinical pharmacology"-- |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Huang, Shiew Mei, |
| Relator term | editor. |
| 9 (RLIN) | 27518 |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Lertora, Juan J.L, |
| Relator term | editor. |
| 9 (RLIN) | 27519 |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Vicini, Paolo, |
| Relator term | editor. |
| 9 (RLIN) | 27520 |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Atkinson, Jr, Arthur J, |
| Relator term | editor. |
| 9 (RLIN) | 27521 |
| 906 ## - LOCAL DATA ELEMENT F, LDF (RLIN) | |
| a | 0 |
| b | ibc |
| c | orignew |
| d | 2 |
| e | epcn |
| f | 20 |
| g | y-gencatlg |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) | |
| Source of classification or shelving scheme | Library of Congress Classification |
| Koha item type | Books |
| Classification part | RM105 |
| Call number prefix | RM105 |
| Call number suffix | .A85 |
| Withdrawn status | Lost status | Source of classification or shelving scheme | Damaged status | Not for loan | Home library | Current library | Shelving location | Date acquired | Source of acquisition | Inventory number | Total Checkouts | Full call number | Barcode | Date last seen | Price effective from | Koha item type | Copy number |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Library of Congress Classification | Zetech Library - Mang'u Campus | Zetech Library - Mang'u Campus | General Stacks | 27/01/2025 | Purchase | 10602 | RM105 .A85 2022 | Z012328 | 27/01/2025 | 27/01/2025 | Books | ||||||
| Library of Congress Classification | Zetech Library - Mang'u Campus | Zetech Library - Mang'u Campus | General Stacks | 27/01/2025 | Purchase | 10601 | RM105 .A85 2022 | Z012327 | 27/01/2025 | 27/01/2025 | Books | C1 |